Donald Trump Pharma Tariff: The US government has excluded companies setting up their manufacturing plants in the US from the scope of the 100 percent tariff on the import of branded and patented medicines.

Donald Trump Pharma Tariff: Last week, US President Donald Trump announced a 100 percent tariff on the import of branded and patented medicines. This tariff is expected to take effect on October 1, 2025. Companies that are building their own manufacturing plants in the US are excluded from this tariff. Its purpose is to encourage domestic pharmaceutical production in the US and reduce dependence on foreign companies. However, even after October 1, this tariff has not been implemented. Why? Let's find out. 

Why is there a delay in implementing the tariff? 

The reason behind this delay is that Trump's administration wants to negotiate with pharmaceutical companies to get their manufacturing back on track before imposing tariffs. Additionally, proposals from several companies to reduce drug prices are being considered. The White House has stated that while negotiations are ongoing, the tariff implementation is being delayed, but it could be implemented in the future. This means the threat is not completely averted. If Trump's 100% pharmaceutical tariff is implemented, medicines imported from abroad will become more expensive for patients. Experts also say this could strain relations between trade partners and disrupt the global supply chain. 

Pfizer signs deal with Trump administration. 

Meanwhile, pharmaceutical giant Pfizer has announced a $70 billion investment in the US as part of a deal with the US government. It has also promised to reduce drug prices. This suggests that the company is looking to expand its operations in the US. Meanwhile, pharmaceutical giant Pfizer has announced a $70 billion investment in the US as part of a deal with the US government. It has also promised to reduce drug prices. This suggests that the company is looking to expand its operations in the US.

#BreakingNews: Today, Pfizer announced a historic and voluntary agreement with @POTUS that will ensure American patients pay lower prices for their prescription medicines. With this agreement in place, we can invest even more boldly in the U.S. – fueling growth, creating jobs,… pic.twitter.com/Im8bJl7yXq

— Pfizer Inc. (@pfizer) September 30, 2025

Preparations underway to launch a website in Trump's name 

Meanwhile, according to a report, Trump's administration is considering launching a website that will list discounted medications. This website will help patients purchase discounted medications directly from companies. It could be named "TrumpRx." This means it will function as a search tool that will allow patients to find out which medications are available at what discounts on which platforms.